CAC
RIGL icon

Cowen and Company’s Rigel Pharmaceuticals RIGL Stock Holding History

Cowen and Company’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$5K – 740
2021
Q3 		$5K Sell
1,000
-7,530
-88% -$296K ﹤0.01% 542
2021
Q2 		$104K Sell
8,530
-2,160
-20% -$81.5K 0.01% 342
2021
Q1 		$77K Buy
10,690
+4,220
+65% +$167K 0.01% 346
2020
Q4 		$32K Buy
6,470
+2,720
+73% +$78.7K ﹤0.01% 302
2020
Q3 		$23K Buy
+3,750
New +$92.1K ﹤0.01% 349

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Cowen and Company's RIGL Position: Q4 2021 in Review

Cowen and Company sold out of Rigel Pharmaceuticals (RIGL) in Q4 2021, closing a stake of 239 shares — an estimated $9K sold.

Cowen and Company first reported a position in RIGL in Q1 2021 and held it in 3 quarters. The position peaked at $266K in Q2 2021. 162 funds tracked by Wall St. Rank hold RIGL as of Q4 2021.

  • Cowen and Company reported no remaining Rigel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Cowen and Company sold 239 Rigel Pharmaceuticals shares in Q4 2021, an estimated $9K.
  • Cowen and Company first reported a position in Rigel Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Cowen and Company's Rigel Pharmaceuticals position peaked at $266K in Q2 2021.
  • 162 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.